Getagraph.com logo
S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-3.32%) $1.920
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Sanntidsoppdatering for Inhibrx, Inc. [INBX]

Børs: NASDAQ Sektor: Healthcare Industri: Biotechnology
BUY
50.00%
return 0.12%
SELL
0.00%
return 1.78%
Sist oppdatert26 apr 2024 @ 22:00
25% discount on Stockinvest.us - Use code: Podcast

-0.09% $ 34.06

SELG 105171 min ago

@ $37.88

Utstedt: 14 feb 2024 @ 15:30

Avkastning: -10.08%

Forrige signal: feb 13 - 15:30

Forrige signal: Kjøp

Avkastning: 2.07 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency...

Stats
Dagens volum 189 853
Gjennomsnittsvolum 477 452
Markedsverdi 1.61B
EPS $0 ( 2024-03-04 )
Neste inntjeningsdato ( $-1.040 ) 2024-05-13
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -6.65
ATR14 $0.0100 (0.03%)
Insider Trading
Date Person Action Amount type
2024-03-26 Deck Kelly Sell 625 Stock Option (right to buy)
2024-03-26 Deck Kelly Sell 396 Stock Option (right to buy)
2024-03-26 Deck Kelly Sell 1 459 Stock Option (right to buy)
2024-03-26 Deck Kelly Sell 416 Stock Option (right to buy)
2024-03-20 Deck Kelly Sell 16 777 Stock Option (right to buy)
INSIDER POWER
56.17
Last 100 transactions
Buy: 3 248 725 | Sell: 1 114 859

Volum Korrelasjon

Lang: -0.04 (neutral)
Kort: 0.24 (neutral)
Signal:(51.137) Neutral

Inhibrx, Inc. Korrelasjon

10 Mest positive korrelasjoner
BIOC0.929
NCBS0.92
FSFG0.918
SNPX0.911
SPFI0.906
BGFV0.905
EQBK0.905
SGMA0.904
PDBC0.903
ADTX0.903
10 Mest negative korrelasjoner
GDNR-0.918
BTWN-0.917
EZGO-0.906
LUNA-0.904
BRAC-0.903
MLCO-0.902
MLVF-0.902
AVAC-0.902
CBAY-0.9
IIN-0.899

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Inhibrx, Inc. Korrelasjon - Valuta/Råvare

The country flag -0.27
( neutral )
The country flag -0.44
( neutral )
The country flag 0.00
( neutral )
The country flag -0.36
( neutral )
The country flag -0.07
( neutral )
The country flag -0.05
( neutral )

Inhibrx, Inc. Økonomi

Annual 2023
Omsetning: $1.80M
Bruttogevinst: $609 000 (33.83 %)
EPS: $-5.12
FY 2023
Omsetning: $1.80M
Bruttogevinst: $609 000 (33.83 %)
EPS: $-5.12
FY 2022
Omsetning: $2.18M
Bruttogevinst: $-668 000 (-30.67 %)
EPS: $-3.62
FY 2021
Omsetning: $7.13M
Bruttogevinst: $0.00 (0.00 %)
EPS: $-2.15

Financial Reports:

No articles found.

Inhibrx, Inc.

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Om Live Signaler

Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.

Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.